Fda grants rmat designation for engene's detalimogene, enabling potential for expedited review in high-risk, non-muscle invasive bladder cancer

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, or “engene” or the “company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the u.s. food and drug administration (fda) has granted regenerative medicine advanced therapy (rmat) designation to detalimogene voraplasmid (also known as detalimogene, and previously eg-70), the company's lead investigational therapy for the treatment of high-risk, bacillus calmette-guÉrin (bcg)-unresponsive,.
ENGN Ratings Summary
ENGN Quant Ranking